格列美脲对2型糖尿病合并冠心病患者纤溶酶原激活物抑制剂-1的影响  

COMPARISON OF GUMEPIRIDE AND METFORMIN ON PLASMINOGEN ACTIVATOR INHIBITOR-1 IN CORONARY HEART DISEASE(CHD) PATIENTS ACCOMPANIED WITH TYPE 2 DIABETES MELLITUS(T2DM)

作　　者：禤文婷[1] 刘玉华[1] 黄娇平[1] 叶筠茹[1] 刘衬连[1] 

机构地区：[1]东莞市人民医院,广东东莞523018

出　　处：《现代医院》2012年第7期44-45,共2页Modern Hospitals

摘　　要：目的探讨格列美脲、二甲双胍对2型糖尿病(T2DM)合并冠心病患者纤溶酶原激活物抑制剂-1的影响。方法 70例T2DM合并冠心病患者分别接受格列美脲、二甲双胍治疗,比较二组治疗3个月前后纤溶酶原激活剂抑制物1(Plasminogen Activator Inhibitor-1,PAI-1)浓度的变化。结果与治疗前相比,格列美脲治疗3个月较治疗前明显降低PAI-1,差异有统计学意义(p<0.05);二甲双胍治疗前后PAI-1比较差异有统计学意义(p<0.05)。结论对2型糖尿病(T2DM)合并冠心病患者格列美脲具有快速稳定控制血糖、显著降低PAI-1水平的作用。Objective To compare the effects of glimepiride and metformin on plasminogen activator inhibi- tor - 1 in coronary heart disease （CHD） patients accompanied with Type 2 diabetes mellitus （T2DM）. Methods A total of 70 CHD patients accompanied with T2DM was received glimepiride （n = 35 ） or metformin （n = 35 ） for 12 weeks. We observed the level plasminogen activator inhibitor type 1 （PAl - 1 ） before and after a 12 - weeks of treatment. Results After 12 weeks with glimepiride or metformin treatment, there was an significant reductions in the level of PAl - 1. Conclusion Glimepiride can rapidly and stably improve glycemic control and reduction the level of PAI- 1 in CHD patients accompanied with T2DM.

关 键 词：格列美脲 二甲双胍 冠心病 2型糖尿病 纤溶酶原激活剂抑制物-1 

分 类 号：R541.4[医药卫生—心血管疾病]